10 hrs ago
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment
Leading Toward the Submission of Application for Marketing Authorization in Europe Tokyo, July 31, 2014 - - Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency for its in-house developed anticancer agent lenvatinib mesylate in the treatment of ... (more)
Lexicon Announces Appointment of Lonnel Coats as President and Chief Executive Officer
Lexicon Pharmaceuticals, Inc. announced today that Lonnel Coats has been appointed president and chief executive officer effective July 7, 2014.
Eisai Receives European Commission Approval of Indication Expansion...
Eisai Co., Ltd. announced today that it has received approval from the European Commission of the indication expansion of Halaven to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease.